# Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

> **NCT03276832** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Melanoma
- Stage IIIB Cutaneous Melanoma AJCC v7
- Stage IIIC Cutaneous Melanoma AJCC v7
- Stage IV Cutaneous Melanoma AJCC v6 and v7

## Interventions

- **DRUG:** Imiquimod
- **PROCEDURE:** Biopsy
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT03276832
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2019-10-15
- **Final completion:** 2019-10-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276832, "Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03276832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*